Widecells Updated Note

14 July 2017

WideCells’ recent launch of CellPlan stem cell insurance/medical concierge service marked an important transition for this fast moving company. In less than one year, WideCells has established a platform to market CellPlan to new and existing umbilical cord blood storage clients and established complimentary businesses in stem cell storage/processing, research and education. WideCells offers an attractive investment opportunity linked to the burgeoning field of stem cell science that is largely without scientific or insurance risk.

To view Shard Capital’s updated note please click the link below:

Widecells update 12th July 2017